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DESCRIPTION of CASE
A
21-year-old pregnant woman, gravida 2 para 1, 
presented with hypertension and proteinuria at 20 
weeks of gestation. She had a history of pre-eclampsia 
in her first pregnancy one year ago. During that pregnancy, 
at 39 weeks of gestation, she developed high blood pressure, 
proteinuria, and deranged liver function. She eventually 
delivered by emergency caesarean section following failed 
induction of labour. Blood pressure returned to normal 
post-partum and she received no further medical follow-up. 
Family history was remarkable for her mother’s diagnosis 
of hypertension in her fourth decade. Her father and five 
siblings, including a twin sister, were healthy. She did not 
smoke nor drink any alcohol. She was not taking any regular 
medications, health products, or herbs. 
At 20 weeks of gestation, blood pressure was found to be 
elevated at 145/100 mmHg during a routine antenatal clinic 
visit. Aside from a mild headache, she reported no other 
symptoms. On physical examination, she was tachycardic with 
heart rate 100 beats per minute. Body mass index was 16.9 
kg/m2 and she had no cushingoid features. Heart sounds 
were normal, and there were no signs suggestive of congestive 
heart failure. Radial-femoral pulses were congruent, and 
there were no audible renal bruits. 
Baseline laboratory investigations showed normal renal 
and liver function with normal serum urate concentration. 
Random glucose was 3.8 mmol/l. Complete blood count 
revealed microcytic anaemia with haemoglobin level 8.3 
g/dl (normal range 11.5–14.3 g/dl) and a slightly raised 
platelet count of 446 × 109/l (normal range 140–380 × 
109/l). Iron-deficient state was subsequently confirmed. 
Quantitation of urine protein indicated mild proteinuria with 
protein:creatinine ratio of 40.6 mg/mmol (normal range <30 
mg/mmol in pregnancy). 
What Were Our Differential Diagnoses?
An important cause of hypertension that occurs during 
pregnancy is pre-eclampsia. It is a condition unique to the 
gravid state and is characterised by the onset of raised blood 
pressure and proteinuria in late pregnancy, at or after 20 
weeks of gestation [1]. Pre-eclampsia may be associated 
with hyperuricaemia, deranged liver function, and signs of 
neurologic irritability such as headaches, hyper-reflexia, and 
seizures. In our patient, hypertension developed at a relatively 
early stage of pregnancy than is customarily observed in 
pre-eclampsia. Although she had proteinuria, it should be 
remembered that this could also reflect underlying renal 
damage due to chronic untreated hypertension. Additionally, 
her electrocardiogram showed left ventricular hypertrophy, 
which was another indicator of chronicity. 
While pre-eclampsia might still be a potential cause of 
hypertension in our case, the possibility of pre-existing 
hypertension needed to be considered. Box 1 shows the 
differential diagnoses of chronic hypertension, including 
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The Learning Forum discusses an important clinical problem of relevance 
to a general medical audience.
Box 1: Causes of Hypertension in Pregnancy
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essential hypertension, primary hyperaldosteronism related to 
Conn’s adenoma or bilateral adrenal hyperplasia, Cushing’s 
syndrome, phaeochromocytoma, renal artery stenosis, 
glomerulopathy, and coarctation of the aorta. 
Renal causes of hypertension were excluded based on 
normal serum creatinine and a bland urinalysis. Serology for 
anti-nuclear antibodies was negative. Doppler ultrasonography 
of renal arteries showed normal flow and no evidence of 
stenosis. Cushing’s syndrome was unlikely as she had no 
clinical features indicative of hypercortisolism, such as moon 
face, buffalo hump, violaceous striae, thin skin, proximal 
muscle weakness, or hyperglycaemia. Plasma potassium 
concentration was normal, although normokalaemia does 
not rule out primary hyperaldosteronism. Progesterone 
has anti-mineralocorticoid effects, and increased placental 
production of progesterone may mask hypokalaemia. Besides, 
measurements of renin activity and aldosterone concentration 
are difficult to interpret as the renin-angiotensin-
aldosterone axis is typically stimulated in pregnancy. 
Phaeochromocytoma is a rare cause of hypertension in 
pregnancy that, if unrecognised, is associated with significant 
maternal and foetal morbidity and mortality. The diagnosis 
can be established by measuring levels of catecholamines 
(noradrenaline and adrenaline) and/or their metabolites 
(normetanephrine and metanephrine) in plasma or urine. 
What Was the Diagnosis?
Catecholamine levels in 24-hour urine collections were 
found to be markedly raised. Urinary noradrenaline 
excretion was markedly elevated at 5,659 nmol, 8,225 nmol, 
and 9,601 nmol/day in repeated collections at 21 weeks 
of gestation (normal range 63–416 nmol/day). Urinary 
adrenaline excretion was normal. Pregnancy may induce 
mild elevation of catecholamine levels, but the marked 
elevation of urinary catecholamine observed was diagnostic 
of phaeochromocytoma. Conditions that are associated with 
false positive results, such as acute myocardial infarction, 
congestive heart failure, acute cerebrovascular event, 
withdrawal from alcohol, withdrawal from clonidine, and 
cocaine abuse, were not present in our patient. 
The working diagnosis was therefore phaeochromocytoma 
complicating pregnancy. Magnetic resonance imaging (MRI) 
of neck to pelvis, without gadolinium enhancement, was 
performed at 24 weeks of gestation. It showed a 4.2 cm solid 
lesion in the mid-abdominal aorto-caval region, while both 
adrenals were unremarkable. There were no ectopic lesions 
seen in the rest of the examined areas. Based on existing 
investigation findings, it was concluded that she had extra-
adrenal paraganglioma resulting in hypertension.
What Was the Next Step in Management?
At 22 weeks of gestation, the patient was started on 
phenoxybenzamine titrated to a dose of 30 mg in the 
morning and 10 mg in the evening. Propranolol was added 
several days after the commencement of phenoxybenzamine. 
Apart from mild postural dizziness, the medical therapy was 
well tolerated during the remainder of the pregnancy. In the 
third trimester, systolic and diastolic blood pressures were 
maintained to below 90 mmHg and 60 mmHg, respectively. 
During this period, she developed mild elevation of alkaline 
phosphatase ranging from 91 to 188 IU/l (reference 35–85 
IU/l). However, liver transaminases were normal and 
the patient had no seizures. Repeated urinalysis showed 
resolution of proteinuria. At 38 weeks of gestation, the 
patient proceeded to elective caesarean section because of 
previous caesarean section, and a live female baby weighing 
3.14 kg was delivered. The delivery was uncomplicated and 
blood pressure remained stable. 
Progress
Following the delivery, computer tomography (CT) scan 
of neck, abdomen, and pelvis was performed as part of pre-
doi:10.1371/journal.pmed.1000037.g001
Figure 1. Computer Tomography Revealing an Extra-Adrenal Paraganglioma in the Celiac Region, Measuring 4.5 cm in Diameter PLoS Medicine  |  www.plosmedicine.org 0171 February 2009  |  Volume 6  |  Issue 2  |  e1000037
operative planning to better delineate the relationship of 
the tumour to neighbouring structures. In addition to the 
previously identified extra-adrenal paraganglioma in the 
abdomen (Figure 1), the CT revealed a 9 mm hypervascular 
nodule at the left carotid bifurcation, suggestive of a 
carotid body tumour (Figure 2). The patient subsequently 
underwent an iodine (I)131 metaiodobenzylguanidine 
(MIBG) scan, which demonstrated marked MIBG-avidity of 
the paraganglioma in the mid-abdomen. The reported left 
carotid body tumour, however, did not demonstrate any 
significant uptake. This could indicate either that the MIBG 
scan had poor sensitivity in detecting a small tumour, or that 
the carotid body tumour was not functional. 
In June 2008, four months after the delivery, the 
patient had a laparotomy with removal of the abdominal 
paraganglioma. The operation was uncomplicated. There 
was no wide fluctuation of blood pressures intra- and post-
operatively. Phenoxybenzamine and propranolol were 
stopped after the operation. Histology of the excised tumour 
was consistent with paraganglioma with cells staining positive 
for chromogranin (Figures 3 and 4) and synaptophysin. 
Adrenal tissues were notably absent. 
The patient was counselled for genetic testing for 
hereditary phaeochromocytoma/paraganglioma. She was 
found to be heterozygous for c.449_453dup mutation of the 
succinate dehydrogenase subunit D (SDHD) gene (Figure 5). This 
mutation is a novel frameshift mutation, and leads to SDHD 
deficiency (GenBank accession number: 1162563). At the 
latest clinic visit in August 2008, she was asymptomatic and 
normotensive. Measurements of catecholamine in 24-hour 
urine collections had normalised. Resection of the left carotid 
body tumour was planned for a later date. She was to be 
followed up indefinitely to monitor for recurrences. She was 
also advised to contact family members for genetic testing. 
Our patient gave written consent for this case to be published. 
DISCUSSION
Phaeochromocytoma in Pregnancy
Hypertension during pregnancy is a frequently encountered 
obstetric complication that occurs in 6%–8% of pregnancies 
[2]. Phaeochromocytoma presenting for the first time in 
pregnancy is rare, and only several hundred cases have 
doi:10.1371/journal.pmed.1000037.g002
Figure 2. Computer Tomography Showing a 9 mm Well-Defined 
Hypervascular Nodule Present in Left Carotid Bifurcation, Suggestive 
of a Carotid Body Tumour
doi:10.1371/journal.pmed.1000037.g003
Figure 3. Macroscopic Appearance of the Resected Para-Aortic Mass
The tumour is a well-circumscribed fleshy yellowish mass with maximal 
dimension of 5.5 cm.
doi:10.1371/journal.pmed.1000037.g004
Figure 4. Histological Section of the Resected Tumour
The tumour cells are polygonal with bland nuclei. The cells are arranged 
in nests and are immunoreactive to chromogranin (shown here) and 
synaptophysin.PLoS Medicine  |  www.plosmedicine.org 0172 February 2009  |  Volume 6  |  Issue 2  |  e1000037
been reported in the English literature. In a recent review 
of 41 cases that presented during 1988 to 1997, maternal 
mortality was 4% while the rate of foetal loss was 11% [3]. 
Antenatal diagnosis was associated with substantial reduction 
in maternal mortality but had little impact on foetal mortality. 
Further, chronic hypertension, regardless of aetiology, 
increases the risk of pre-eclampsia by 10-fold [1].
Classically, patients with phaeochromocytoma present 
with spells of palpitation, headaches, and diaphoresis 
[4]. Hypertension may be sustained or sporadic, and is 
associated with orthostatic blood pressure drop because of 
hypovolaemia and impaired vasoconstricting response to 
posture change. During pregnancy, catecholamine surge 
may be triggered by pressure from the enlarging uterus and 
foetal movements. In the majority of cases, catecholamine-
secreting tumours develop in the adrenal medulla and 
are termed phaeochromocytoma. Ten percent of tumours 
arise from extra-adrenal chromaffin tissues located in the 
abdomen, pelvis, or thorax to form paraganglioma that may 
or may not be biochemically active. The malignant potential 
of phaeochromocytoma or paraganglioma cannot be 
determined from histology and is inferred by finding tumours 
in areas of the body not known to contain chromaffin tissues. 
The risk of malignancy is higher in extra-adrenal tumours 
and in tumours that secrete dopamine. 
Making the Correct Diagnosis 
The diagnosis of phaeochromocytoma requires a 
combination of biochemical and anatomical confirmation. 
Catecholamines and their metabolites, metanephrines, 
can be easily measured in urine or plasma samples. Day 
collection of urinary fractionated metanephrine is considered 
the most sensitive in detecting phaeochromocytoma [5]. 
In contrast to sporadic release of catecholamine, secretion 
of metanephrine is continuous and is less subjective 
to momentary stress. Localisation of tumour can be 
accomplished by either CT or MRI of the abdomen [6]. 
Sensitivities are comparable, although MRI is preferable in 
pregnancy because of minimal radiation exposure. Once a 
tumour is identified, nuclear medicine imaging should be 
performed to determine its activity, as well as to search for 
extra-adrenal diseases. I131 or I123 MIBG scan is the imaging 
modality of choice. Metaiodobenzylguanidine structurally 
resembles noradrenaline and is concentrated in chromaffin 
cells of phaeochromocytoma or paraganglioma that express 
noradrenaline transporters. Radionucleotide imaging is 
contraindicated in pregnancy and should be deferred until 
after the delivery. 
Treatment Approach
Upon confirming the diagnosis, medical therapy should 
be initiated promptly to block the cardiovascular effects 
of catecholamine release. Phenoxybenzamine is a long-
acting non-selective alpha-blocker commonly used in 
phaeochromocytoma to control blood pressure and prevent 
cardiovascular complications [7]. The main side-effects of 
phenoxybenzamine are postural hypotension and reflex 
tachycardia. The latter can be circumvented by the addition 
of a beta-blocker. It is important to note that beta-blockers 
should not be used in isolation, since blockade of β2-
adrenoceptors, which have a vasodilatory effect, can cause 
unopposed vasoconstriction by α1-adrenoceptor stimulation 
and precipitate severe hypertension. There is little data 
on the safety of use of phenoxybenzamine in pregnancy, 
although its use is deemed necessary and probably life-saving 
in this precarious situation. 
doi:10.1371/journal.pmed.1000037.g005
Figure 5. Sequence Chromatogram Showing the Novel Frameshift Mutation of the SDHD Gene: c.449_453dup (p.Val153LysfsX17)PLoS Medicine  |  www.plosmedicine.org 0173 February 2009  |  Volume 6  |  Issue 2  |  e1000037
The definitive treatment of phaeochromocytoma or 
paraganglioma is surgical excision. The timing of surgery 
is critical, and the decision must take into consideration 
risks to the foetus, technical difficulty regarding access to 
the tumour in the presence of a gravid uterus, and whether 
the patient’s symptoms can be satisfactorily controlled with 
medical therapy [8,9]. It has been suggested that surgical 
resection is reasonable if the diagnosis is confirmed and the 
tumour identified before 24 weeks of gestation. Otherwise, it 
may be preferable to allow the pregnancy to progress under 
adequate alpha- and beta-blockade until foetal maturity is 
reached. Unprepared delivery is associated with a high risk 
of phaeochromocytoma crisis, characterised by labile blood 
pressure, tachycardia, fever, myocardial ischaemia, congestive 
heart failure, and intracerebral bleeding. 
Patients with phaeochromocytoma or paraganglioma 
should be followed up for life. The rate of recurrence is 
estimated to be 2%–4% at five years [10]. Assessment for 
recurrent disease can be accomplished by periodic blood 
pressure monitoring and 24-hour urine catecholamine and/
or metanephrine measurements. 
Genetics of Phaeochromocytoma 
Approximately one quarter of patients presenting with 
phaeochromocytoma may carry germline mutations, 
even in the absence of apparent family history [11]. The 
common syndromes of hereditary phaeochromocytoma/
paraganglioma are listed in Box 2. These include Von 
Hippel-Lindau syndrome, multiple endocrine neoplasia 
type 2, neurofibromatosis type 1, and succinate dehydrogenase 
(SDH) gene mutations. Our patient has a novel frameshift 
mutation in the SDHD gene located at Chromosome 
11q. SDH is a mitochondrial enzyme that is involved 
in oxidative phosphorylation. Characteristically, SDHD
mutation is associated with head or neck non-functional 
paraganglioma, and infrequently, sympathetic paraganglioma 
or phaeochromocytoma [12]. Tumours associated with 
SDHD mutation are rarely malignant, in contrast to those 
arisen from mutation of the SDHB gene. Like all other 
syndromes of hereditary phaeochromocytoma, SDHD
mutation is transmitted in an autosomal dominant fashion. 
However, not all carriers of the SDHD mutation develop 
tumours, and inheritance is further complicated by 
maternal imprinting in gene expression. While it may not 
be practical to screen for genetic alterations in all cases of 
phaeochromocytoma, most authorities advocate genetic 
screening for patients with positive family history, young age 
of tumour onset, co-existence with other neoplasms, bilateral 
phaeochromocytoma, and extra-adrenal paraganglioma. The 
confirmation of genetic mutation should prompt evaluation 
of other family members.
Conclusion
Phaeochromocytoma complicating pregnancy is uncommon. 
Nonetheless, in view of the potential for catastrophic 
consequences if unrecognised, a high index of suspicion and 
careful evaluation for secondary causes of hypertension is of 
utmost importance. Blood pressure should be monitored in 
the post-partum period and persistence of hypertension must 
be thoroughly investigated.  
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Key Learning Points 
sÈ (YPERTENSIONÈCOMPLICATINGÈPREGNANCYÈISÈAÈCOMMONLYÈ
encountered medical condition.
sÈ 0RE
EXISTINGÈCHRONICÈHYPERTENSIONÈMUSTÈBEÈCONSIDEREDÈ
in patients with hypertension presenting in pregnancy, 
particularly if elevation of blood pressure is detected early 
during pregnancy or if persists post-partum.
sÈ 3ECONDARYÈCAUSESÈOFÈCHRONICÈHYPERTENSIONÈINCLUDEÈRENALÈ
artery stenosis, renal parenchyma disease, primary 
HYPERALDOSTERONISMÈPHAEOCHROMOCYTOMAÈ#USHINGSÈ
syndrome, coarctation of the aorta, and obstructive sleep 
apnoea.
sÈ 0HAEOCHROMOCYTOMAÈPRESENTINGÈDURINGÈPREGNANCYÈISÈRAREÈ
but carries high rates of maternal and foetal morbidity and 
mortality if unrecognised.
sÈ 3UCCESSFULÈOUTCOMESÈDEPENDÈONÈEARLYÈDISEASEÈIDENTIFICATIONÈ
prompt initiation of alpha- and beta-blockers, carefully 
planned delivery, and timely resection of the tumour. 
Box 2: Hereditary Phaeochromocytoma/
Paraganglioma Syndromes
sÈ 6ONÈ(IPPEL
,INDAUÈSYNDROME
sÈ -ULTIPLEÈENDOCRINEÈNEOPLASIAÈTYPEÈ!ÈANDÈTYPEÈ"
sÈ .EUROFIBROMATOSISÈTYPEÈ
sÈ -UTATIONÈOFÈSDHB, SDHC, SDHD
sÈ !TAXIA
TELANGIECTASIA
sÈ 4UBEROUSÈSCLEROSIS
sÈ 3TURGE
7EBERÈSYNDROME